iShares MSCI Switzerland ETF
iShares · Tracks MSCI Switzerland 25/50 Index · Inception Mar 12, 1996
Composite score
Based on a 0.50% expense ratio.
Based on $1.97B in net assets.
Top-10 holdings represent 67.4% of net assets.
International Developed base · ETF wrapper · 1.72% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use EWL in our tools
Tool · Cost
Compare EWL's fee against another fund
Compounds the 0.50% expense ratio against a peer over decades.
Tool · Overlap
Compare EWL's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar International Developed funds.
Tool · TLH
Find a tax-loss harvesting partner for EWL
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | Roche Holding AG | 14.78% |
| 2 | Novartis AG | 14.11% |
| 3 | Nestle S.A. | 12.46% |
| 4 | UBS Group AG | 5.54% |
| 5 | ABB Ltd | 5.11% |
| 6 | Zurich Insurance Group AG | 4.11% |
| 7 | COMPAGNIE FINANCIERE RICHEMONT SA | 3.91% |
| 8 | Swiss Re AG | 2.60% |
| 9 | Lonza Group AG | 2.44% |
| 10 | Holcim AG | 2.35% |
Compare EWL with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open EWL at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.